VKTXViking Therapeutics, Inc.Healthcare · Biotechnologyas of 2026-09-25
Horizon

Issued 2026-09-25 at $35.56 · now $35.56 (2026-09-25, +0.0% since)

Based on its own history, a month from the 2026-09-25 close, VKTX has typically landed between $26.54 and $51.64 — a range of −25.4% to +45.2% from the issuance price $35.56.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

2,844 overlapping 1 month windows · 2015-04-28 – 2026-08-26 · basis climatology · forecast (batch). Base rate up 53.7% (90% CI 51.5–55.9%, ≈1,391 obs). Not a call on this stock — we have no evidence its odds differ.

The cone is anchored at the 2026-09-25 issuance close ($35.56) — the price the forecast resolves against on 2026-10-26, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where VKTX has typically landed a month from the 2026-09-25 close of $35.56 — the range is history, not a prediction.

$26.54worst · -25.4%$51.64best · +45.2%
  • now $35.56 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $35.08 (-1.4%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $30.19–$39.97
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $26.54–$51.64
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 2,844 windows spanning 2015-04-28 to 2026-09-25. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2015-11-17−58.2%−58.2%+0.0%
2015-11-18−57.6%−57.6%+0.0%
2015-11-16−57.4%−57.4%+0.0%
3 best
2024-01-26+342.2%+0.0%+342.2%
2024-02-02+288.8%+0.0%+303.0%
2024-01-31+278.4%−2.9%+291.5%

2,844 overlapping windows · 2015-04-28 – 2026-09-25 · not cherry-picked

Pending catalysts

  • 2027-07-01 — Trial primary completion: Phase 3 primary completion: VK2735 for Weight Management Phase 3 (source, as of 2026-08-14)
  • 2027-07-01 — Trial primary completion: Phase 3 primary completion: VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) (source, as of 2026-08-14)

Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~12 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
45%
−0.7%
n=11
Feb
55%
+22.1%
n=11
Mar
27%
−3.5%
n=11
Apr
45%
+1.3%
n=11
May
33%
−2.5%
n=12
Jun
50%
+7.6%
n=12
Jul
50%
−0.1%
n=12
Aug
50%
+1.4%
n=12
Sep
33%
+5.6%
n=12
Oct
36%
+5.2%
n=11
Nov
45%
−1.8%
n=11
Dec
55%
+14.3%
n=11

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$42$232026-07-29: 3 insider sales, $6.3M — Lian Brian, ZANTE GREG, Mancini Marianna2026-03-10: 1 insider purchase, $150K — Aubuchon Neil William2026-01-05: 12 insider sales, $11.5M — Lian Brian, ZANTE GREG, Mancini Marianna …2026-01-02: 1 insider sale, $562K — FOEHR MATTHEW W2025-10-28: 3 insider sales, $1.8M — Lian Brian, Mancini Marianna, ZANTE GREG2025-10-27: 1 insider sale, $2.1M — Rowland Charles A Jr2025-10: 4 open-market sales, $3.9M2026-01: 13 open-market sales, $12.1M2026-03: 1 open-market purchase, $150K2026-07: 3 open-market sales, $6.3M↑ buys↓ salesdirector Lian Brian — Sale on 2026-07-29, filed same dayofficer ZANTE GREG — Sale on 2026-07-29, filed same dayofficer Mancini Marianna — Sale on 2026-07-29, filed same dayofficer Aubuchon Neil William — Purchase on 2026-03-10, filed same daydirector Lian Brian — Sale on 2026-01-05, filed same daydirector Lian Brian — Sale on 2026-01-05, filed same daydirector Lian Brian — Sale on 2026-01-05, filed same dayofficer ZANTE GREG — Sale on 2026-01-05, filed same dayofficer Mancini Marianna — Sale on 2026-01-05, filed same dayofficer ZANTE GREG — Sale on 2026-01-05, filed same dayofficer Mancini Marianna — Sale on 2026-01-05, filed same dayofficer Mancini Marianna — Sale on 2026-01-05, filed same dayofficer ZANTE GREG — Sale on 2026-01-05, filed same daydirector Lian Brian — Sale on 2026-01-05, filed same dayofficer Mancini Marianna — Sale on 2026-01-05, filed same dayofficer ZANTE GREG — Sale on 2026-01-05, filed same daydirector FOEHR MATTHEW W — Sale on 2026-01-02, filed 3 days after the tradedirector Lian Brian — Sale on 2025-10-28, filed same dayofficer Mancini Marianna — Sale on 2025-10-28, filed same dayofficer ZANTE GREG — Sale on 2025-10-28, filed same daydirector Rowland Charles A Jr — Sale on 2025-10-27, filed 1 day after the trade
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2026-07-29Lian BriandirectorSale148,517 @ $33.32$4.9M−5.5% of holding−4.4%not yet — horizon still open2,572,441Form 4 · filed same day
2026-07-29ZANTE GREGofficerSale21,217 @ $33.47$710K−9.1% of holding−4.4%not yet — horizon still open212,204Form 4 · filed same day
2026-07-29Mancini MariannaofficerSale18,217 @ $33.47$610K−4.1% of holding−4.4%not yet — horizon still open422,760Form 4 · filed same day
2026-03-10Aubuchon Neil WilliamofficerPurchase4,475 @ $33.50$150Kownership Δ n/a+0.2%−18.8%4,475Form 4 · filed same day
2026-01-05Lian BriandirectorSale132,454 @ $32.29$4.3M−4.8% of holding−7.8%+15.4%2,600,246Form 4 · filed same day
2026-01-05Lian BriandirectorSale53,279 @ $33.38$1.8M−2.0% of holding−7.8%+15.4%2,546,967Form 4 · filed same day
2026-01-05Lian BriandirectorSale41,276 @ $34.22$1.4M−1.6% of holding−7.8%+15.4%2,505,691Form 4 · filed same day
2026-01-05ZANTE GREGofficerSale31,961 @ $32.30$1.0M−12.9% of holding−7.8%+15.4%215,571Form 4 · filed same day
2026-01-05Mancini MariannaofficerSale31,961 @ $32.29$1.0M−6.8% of holding−7.8%+15.4%434,890Form 4 · filed same day
2026-01-05ZANTE GREGofficerSale13,900 @ $33.38$464K−6.4% of holding−7.8%+15.4%201,671Form 4 · filed same day
2026-01-05Mancini MariannaofficerSale13,600 @ $33.37$454K−3.1% of holding−7.8%+15.4%421,290Form 4 · filed same day
2026-01-05Mancini MariannaofficerSale10,500 @ $34.22$359K−2.5% of holding−7.8%+15.4%410,790Form 4 · filed same day
2026-01-05ZANTE GREGofficerSale10,300 @ $34.24$353K−5.1% of holding−7.8%+15.4%191,371Form 4 · filed same day
2026-01-05Lian BriandirectorSale6,400 @ $35.07$224K−0.3% of holding−7.8%+15.4%2,499,291Form 4 · filed same day
2026-01-05Mancini MariannaofficerSale1,600 @ $35.07$56K−0.4% of holding−7.8%+15.4%409,190Form 4 · filed same day
2026-01-05ZANTE GREGofficerSale1,500 @ $32.09$48K−0.8% of holding−7.8%+15.4%189,891Form 4 · filed same day
2026-01-02FOEHR MATTHEW WdirectorSale16,000 @ $35.11$562K−10.8% of holding−17.9%+8.9%132,036Form 4 · filed 3 days after the trade
2025-10-28Lian BriandirectorSale38,989 @ $35.01$1.4M−1.6% of holding+4.9%−15.9%2,419,109Form 4 · filed same day
2025-10-28Mancini MariannaofficerSale6,185 @ $35.00$216K−1.6% of holding+4.9%−15.9%382,467Form 4 · filed same day
2025-10-28ZANTE GREGofficerSale6,185 @ $35.00$216K−3.4% of holding+4.9%−15.9%173,592Form 4 · filed same day
2025-10-27Rowland Charles A JrdirectorSale60,000 @ $35.57$2.1M−66.7% of holding+0.2%−17.2%30,000Form 4 · filed 1 day after the trade
2025-07-03Lian BriandirectorSale26,889 @ $27.80$748K−1.1% of holding+19.6%+15.8%2,388,014Form 4 · filed same day
2025-07-03Mancini MariannaofficerSale4,266 @ $27.77$118K−1.1% of holding+19.6%+15.8%377,535Form 4 · filed same day
2025-07-03ZANTE GREGofficerSale4,266 @ $27.76$118K−2.5% of holding+19.6%+15.8%168,660Form 4 · filed same day
2025-03-31Rouan Sarah KathryndirectorPurchase1,240 @ $24.15$30Kownership Δ n/a+20.4%−11.0%1,240Form 4 · filed 2 days after the trade
2025-01-06Lian BriandirectorSale175,490 @ $42.68$7.5M−6.9% of holding−27.9%−32.2%2,385,570Form 4 · filed same day
2025-01-06Mancini MariannaofficerSale49,115 @ $42.69$2.1M−11.5% of holding−27.9%−32.2%379,234Form 4 · filed same day
2025-01-06Lian BriandirectorSale19,000 @ $43.32$823K−0.8% of holding−27.9%−32.2%2,366,570Form 4 · filed same day
2025-01-06Mancini MariannaofficerSale5,100 @ $43.32$221K−1.3% of holding−27.9%−32.2%374,134Form 4 · filed same day
2024-11-08MACARTNEY LAWSONdirectorSale2,000 @ $68.67$137K−4.0% of holding−30.9%−60.1%47,965Form 4 · filed same day
2024-10-28ZANTE GREGofficerSale49,672 @ $74.56$3.7M−17.7% of holding−31.7%−58.4%231,381Form 4 · filed same day
2024-10-28ZANTE GREGofficerSale23,082 @ $77.68$1.8M−11.3% of holding−31.7%−58.4%180,414Form 4 · filed same day
2024-10-28ZANTE GREGofficerSale18,620 @ $75.79$1.4M−8.0% of holding−31.7%−58.4%212,761Form 4 · filed same day
2024-10-28ZANTE GREGofficerSale15,825 @ $78.69$1.2M−8.8% of holding−31.7%−58.4%164,589Form 4 · filed same day
2024-10-28ZANTE GREGofficerSale9,265 @ $76.94$713K−4.4% of holding−31.7%−58.4%203,496Form 4 · filed same day
2024-10-28ZANTE GREGofficerSale7,967 @ $80.65$643K−5.0% of holding−31.7%−58.4%150,572Form 4 · filed same day
2024-10-28ZANTE GREGofficerSale6,050 @ $79.78$483K−3.7% of holding−31.7%−58.4%158,539Form 4 · filed same day
2024-10-28ZANTE GREGofficerSale1,206 @ $81.44$98K−0.8% of holding−31.7%−58.4%149,366Form 4 · filed same day
2024-10-25SINGLETON J MATTHEWdirectorSale16,000 @ $79.50$1.3M−62.7% of holding−36.6%−59.4%9,500Form 4 · filed same day
2024-10-25Rouan Sarah KathryndirectorSale11,000 @ $80.89$890K−100.0% of holding−36.6%−59.4%0Form 4 · filed same day
2024-09-20Lian BriandirectorSale119,874 @ $71.15$8.5M−4.9% of holding−11.4%−62.2%2,305,127Form 4 · filed same day
2024-09-20Lian BriandirectorSale96,056 @ $70.43$6.8M−3.8% of holding−11.4%−62.2%2,425,001Form 4 · filed same day
2024-09-20SINGLETON J MATTHEWdirectorSale10,300 @ $69.50$716K−52.0% of holding−11.4%−62.2%9,500Form 4 · filed same day
2024-09-20Lian BriandirectorSale200 @ $71.98$14K−0.0% of holding−11.4%−62.2%2,304,927Form 4 · filed same day
2024-08-21SINGLETON J MATTHEWdirectorSale5,700 @ $69.72$397K−37.5% of holding+7.1%−62.1%9,500Form 4 · filed 1 day after the trade
2024-08-21Lian BriandirectorSale1,000 @ $69.90$70K−0.0% of holding+7.1%−62.1%2,354,927Form 4 · filed 1 day after the trade
2024-08-19Lian BriandirectorSale70,132 @ $65.33$4.6M−2.8% of holding−3.6%−62.3%2,397,665Form 4 · filed same day
2024-08-19Lian BriandirectorSale31,442 @ $66.37$2.1M−1.3% of holding−3.6%−62.3%2,366,223Form 4 · filed same day
2024-08-19Lian BriandirectorSale11,296 @ $67.12$758K−0.5% of holding−3.6%−62.3%2,354,927Form 4 · filed same day
2024-08-19SINGLETON J MATTHEWdirectorSale4,509 @ $61.86$279K−22.6% of holding−3.6%−62.3%15,444Form 4 · filed same day
2024-08-19SINGLETON J MATTHEWdirectorSale3,047 @ $61.13$186K−13.2% of holding−3.6%−62.3%19,953Form 4 · filed same day
2024-08-19SINGLETON J MATTHEWdirectorSale2,388 @ $64.10$153K−17.8% of holding−3.6%−62.3%11,001Form 4 · filed same day
2024-08-19SINGLETON J MATTHEWdirectorSale2,500 @ $60.01$150K−9.8% of holding−3.6%−62.3%23,000Form 4 · filed same day
2024-08-19SINGLETON J MATTHEWdirectorSale2,055 @ $63.15$130K−13.3% of holding−3.6%−62.3%13,389Form 4 · filed same day
2024-08-19SINGLETON J MATTHEWdirectorSale1,501 @ $64.88$97K−13.6% of holding−3.6%−62.3%9,500Form 4 · filed same day
2024-08-14SINGLETON J MATTHEWdirectorSale20,626 @ $57.52$1.2M−68.1% of holding+11.3%−60.5%9,660Form 4 · filed same day
2024-08-14SINGLETON J MATTHEWdirectorSale160 @ $58.37$9K−1.7% of holding+11.3%−60.5%9,500Form 4 · filed same day
2024-07-30Lian BriandirectorSale65,941 @ $56.95$3.8M−2.7% of holding+5.2%−52.7%2,404,845Form 4 · filed 1 day after the trade
2024-07-30Lian BriandirectorSale30,417 @ $58.78$1.8M−1.3% of holding+5.2%−52.7%2,354,927Form 4 · filed 1 day after the trade
2024-07-30Lian BriandirectorSale19,501 @ $57.81$1.1M−0.8% of holding+5.2%−52.7%2,385,344Form 4 · filed 1 day after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

112 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-08-01Kelly-Gemmell Dorothy ElizabethdirectorAward / grant6,3336,333Form 4
2026-08-01Kelly-Gemmell Dorothy ElizabethdirectorAward / grant40,80040,800Form 4
2026-07-28Mancini MariannaofficerAward / grant31,667440,977Form 4
2026-07-28ZANTE GREGofficerAward / grant31,667233,421Form 4
2026-07-28Lian BriandirectorAward / grant221,6672,720,958Form 4
2026-06-01Chen Hubert CofficerAward / grant190,000190,000Form 4
2026-01-12Aubuchon Neil WilliamofficerAward / grant180,000180,000Form 4
2026-01-02FOEHR MATTHEW WdirectorOption exercise16,000148,036Form 4
2026-01-02FOEHR MATTHEW WdirectorAward / grant20,40020,400Form 4
2026-01-02FOEHR MATTHEW WdirectorOption exercise16,0000Form 4
2026-01-02FOEHR MATTHEW WdirectorAward / grant3,150135,186Form 4
2026-01-02Lian BriandirectorAward / grant176,300176,300Form 4
2026-01-02Mancini MariannaofficerAward / grant41,000434,802Form 4
2026-01-02Mancini MariannaofficerAward / grant32,049466,851Form 4
2026-01-02Lian BriandirectorAward / grant78,4002,508,620Form 4
2026-01-02Rouan Sarah KathryndirectorAward / grant20,40020,400Form 4
2026-01-02Rouan Sarah KathryndirectorAward / grant3,1504,390Form 4
2026-01-02Mancini MariannaofficerAward / grant91,00091,000Form 4
2026-01-02ZANTE GREGofficerAward / grant41,000215,483Form 4
2026-01-02ZANTE GREGofficerAward / grant32,049247,532Form 4
2026-01-02SINGLETON J MATTHEWdirectorAward / grant20,40020,400Form 4
2026-01-02SINGLETON J MATTHEWdirectorAward / grant3,15012,650Form 4
2026-01-02Rowland Charles A JrdirectorAward / grant20,40020,400Form 4
2026-01-02MACARTNEY LAWSONdirectorAward / grant3,15051,115Form 4
2026-01-02MACARTNEY LAWSONdirectorAward / grant20,40020,400Form 4
2026-01-02Lian BriandirectorAward / grant224,0802,732,700Form 4
2026-01-02ZANTE GREGofficerAward / grant91,00091,000Form 4
2026-01-02Rowland Charles A JrdirectorAward / grant3,15033,150Form 4
2025-10-27Rowland Charles A JrdirectorAward / grant22,00068,000Form 4
2025-10-27Rowland Charles A JrdirectorAward / grant22,00090,000Form 4
2025-10-27Rowland Charles A JrdirectorAward / grant16,00046,000Form 4
2025-10-27Mancini MariannaofficerAward / grant11,117388,652Form 4
2025-10-27Rowland Charles A JrdirectorOption exercise16,0000Form 4
2025-10-27Rowland Charles A JrdirectorOption exercise22,0000Form 4
2025-10-27ZANTE GREGofficerAward / grant11,117179,777Form 4
2025-10-27Lian BriandirectorAward / grant70,0842,458,098Form 4
2025-07-02Lian BriandirectorAward / grant48,3332,414,903Form 4
2025-07-02ZANTE GREGofficerAward / grant7,667172,926Form 4
2025-07-02Mancini MariannaofficerAward / grant7,667381,801Form 4
2025-04-11FOEHR MATTHEW WdirectorOption exercise20,786132,036Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.